P2RY12 and atrial fibrillation: As non-vitamin K antagonist oral anticoagulants (NOACs) had shown a safety benefit in patients with AF compared with conventional vitamin K antagonists (VKAs) [10,11], recent clinical trials have investigated the clinical benefit of dual antithrombotic therapy combining NOAC and P2Y12 antagonists (mostly clopidogrel) as an alternative to triple therapy after PCI in patients with AF [12–15].